Search
Pembrolizumab
Pembrolizumab is a highly selective IgG4-kappa humanized monoclonal antibody against PD-1 receptors. It was generated by grafting the variable sequences of a very high-affinity mouse antihuman PD-1 antibody onto a human IgG4-kappa isotype containing a stabilizing S228P Fc mutation. It contains 32 cysteine residues a...
Berahyaluronidase alfa
go.drugbank.com/drugs/DB22790ApprovedInvestigationalIt is used in a fixed-dose combination with [pembrolizumab] for subcutaneous injection.
Sacituzumab govitecan
go.drugbank.com/drugs/DB12893ApprovedInvestigational[L64779] The European Commission added the first-line monotherapy indication on 22 June 2026 and the first-line combination with pembrolizumab on 21 August 2026.[L64778] … L47606, L47601] The FDA approved first-line TNBC indications on June 24, 2026, as a single agent for patients who are not candidates for PD-1 or PD-L1 inhibitor-based therapy and in combination with pembrolizumab
Belzutifan
go.drugbank.com/drugs/DB15463ApprovedInvestigational[L64571] Its indications were later extended to ccRCC, as monotherapy and in combination with pembrolizumab, and to PPGL.
Advanced Mismatch Repair-deficient (dMMR) Endometrial Carcinoma
go.drugbank.com/conditions/DBCOND0147956Drugs: PembrolizumabAdvanced, unresectable Malignant Pleural Mesothelioma (MPM)
go.drugbank.com/conditions/DBCOND0168860Drugs: PembrolizumabHigh risk, in situ Non-Muscle Invasive Bladder Cancer (NMIBC) Refractory to BCG
go.drugbank.com/conditions/DBCOND0144300Drugs: PembrolizumabMetastatic Malignant Pleural Mesothelioma (MPM)
go.drugbank.com/conditions/DBCOND0168861Drugs: PembrolizumabMetastatic Microsatellite Instability-High (MSI-H) Solid Tumors
go.drugbank.com/conditions/DBCOND0144301Drugs: PembrolizumabResectable, locally advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)
go.drugbank.com/conditions/DBCOND0173428Drugs: Pembrolizumab